Pricing Log in Create free account

InflaRx N.V. (IFRX) vs Inhibikase Therapeutics, Inc. (IKT)

InflaRx N.V. and Inhibikase Therapeutics, Inc. are both Biotechnology companies. InflaRx N.V. and Inhibikase Therapeutics, Inc. are of similar size ($209.3M and $192.3M). Inhibikase Therapeutics, Inc. grew revenue faster over the last twelve months: 110.9% against −83.4%. Across the 13 metrics below, Inhibikase Therapeutics, Inc. leads on 8 and InflaRx N.V. on 5.

Valuation

Metric IFRX IKT Biotechnology median
P/E n/m n/m 10.60
P/S 6,308.89 1,005.21 9.40
P/B 1.16 1.71 2.13
Price to free cash flow n/m n/m 25.18
EV/EBITDA n/m n/m 0.66
EV/Sales 1,845.43 394.78 9.02
Earnings yield (29.70%) (28.67%) (32.88%)
Free cash flow yield (10.67%) (16.28%) (23.13%)

Profitability

Metric IFRX IKT Biotechnology median
Gross margin (26,762.42%) 100.00% 68.51%
Operating margin 0.00% 0.00% 0.00%
Net margin 0.00% 0.00% 0.00%
Free cash flow margin 0.00% 0.00% 0.00%
Return on equity (30.98%) (51.96%) (51.96%)
Return on assets (25.90%) (48.04%) (46.06%)
Return on invested capital (87.31%) 0.00% 0.00%

Growth

Metric IFRX IKT Biotechnology median
Revenue growth (TTM) (83.39%) 110.93% 6.76%
EPS growth (last fiscal year) 9.41% 57.76% 29.88%
Revenue growth, 5-year CAGR — (42.21%) 9.75%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric IFRX IKT Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 7.26 15.82 4.97
Net debt to EBITDA 0.97 3.44 1.01

Dividend

Metric IFRX IKT Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric IFRX IKT Biotechnology median
Market cap 192.32m 209.30m 161.82m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack